Overview

ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Suspected NAFLD

Status:
Completed

Trial end date:
2016-09-08

Target enrollment:

Participant gender:

Summary

A Phase 2a, randomized, double-blind, placebo-controlled, multi-center study of cenicriviroc (CVC) to be conducted in approximately 50 adult obese subjects [body mass index (BMI) ≥ 30 kg/m^2] with prediabetes or type 2 diabetes mellitus and suspected NALFD.

Phase:

Phase 2

Details

Lead Sponsor:

Tobira Therapeutics, Inc.

Treatments:

Cenicriviroc
Insulin
TAK-652